May 31, 2026
Biosimilar Approval: How the FDA Reviews Biologic Alternatives in 2026
The TRIPS agreement shaped global access to generic medicines by enforcing strict patent rules that delay affordable drugs in poor countries. Despite flexibilities like compulsory licensing, legal and political barriers keep life-saving treatments out of reach for millions.